A Study of Efavirenz in Combination With Stavudine and Didanosine
A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients
Sponsor: Dupont Merck
Listed as NCT00002225, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Dupont Merck, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Study Description(click to expand)Patients will be given combination treatment with efavirenz, stavudine, and didanosine.
Patients will be given combination treatment with efavirenz, stavudine, and didanosine.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dupont Merck
For direct contact, visit the study record on ClinicalTrials.gov .